TrialScientific reports2021

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma.

Andrew J Brenner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.